Clinical Trials

Hyundai Bioscience offers a free drug for an untreatable Ebola strain. It's a bold humanitarian gesture, and a masterclass in strategic maneuvering.

One year in, the Facial Pain Registry has gathered data from 740 patients, creating an unprecedented resource to fight one of medicine's most misunderstood conditions.

Millions suffer from chronic sciatica with few good options. A small biotech is betting on a novel, non-opioid drug to fix the problem, not just mask it.

MAIA Biotechnology isn't just opening a new trial site; it's accelerating its assault on a $70B market with a drug showing remarkable early results.

At EHA 2026, Parexel isn't just presenting data; it's unveiling a bold new strategy to fix a broken system and accelerate life-saving blood cancer drugs.

With its pivotal Phase 3 trial complete, Rafael Holdings is on a path to redefine treatment for NPC and transform itself into a commercial-stage biotech.

Health Canada's Priority Review for a new Duchenne muscular dystrophy drug signals hope for patients and a strategic test of Canada's rare disease market.

A UK firm's regulatory milestone is more than just compliance; it's a strategic masterclass in building the resilient systems needed to fight food allergies.

Sanofi's promising nerve disease drug fails in late-stage trials, leaving vulnerable patients in limbo and highlighting the brutal realities of medical innovation.

Mickey Mikitani shifts to Executive Chairman, installing a new CEO to navigate the high-stakes journey from visionary science to U.S. market reality.

Takeda seeks FDA approval for its gut-focused drug ENTYVIO in children, a major step toward a new era of treatment for the rising tide of pediatric IBD.

New long-term data for masitinib shows a near doubling of 5-year survival for ALS patients, with many maintaining quality of life. Is this the turning point?

A Phase 1 trial launch is more than a milestone; it's a look at the future of pharma, where AI-driven speed and strategic global partnerships converge.

Enveric Biosciences heads to a key UBS investor day to pitch its non-hallucinogenic antidepressant, EB-003. Can it secure the capital needed to revolutionize CNS?

Matisse Pharmaceuticals' new sepsis drug just got a major boost from the FDA. But the real story is the invisible infrastructure—both biological and regulatory—it aims to master.

A new clinical trial for a twice-yearly COPD injection could disrupt a multi-billion dollar market, offering hope to millions and validating a novel biotech strategy.

FloBiotech and UCLA Health are betting on a new strategy against neurodegeneration: boosting the brain's own defenses. This alliance could redefine a field long plagued by failure.

A major study combining two powerful cancer drugs, KEYTRUDA and Trodelvy, has been halted, a setback for patients and a reality check for the industry.

With key hires Ulf Wiinberg and Bill MacKenzie, Neuraptive signals a major shift from R&D to market readiness for its nerve repair therapeutic, NTX-001.

With 80% of trials delayed, the life sciences industry is gathering to tackle its patient enrollment crisis. Can new partnerships and AI finally move the needle?